Indegene: Difference between revisions

What links here Related changes Page information Get shortened URL
Created by Kattarshian
Last edited August 18, 2025
VisualWikitext
>Kattarshian
#suggestededit-add 1.0
 
General cleanup and content improvements
 
Line 1: Line 1:
{{Short description|Research and development company offering services to pharmaceutical companies}}
{{Short description|Indian multinational company}}
{{Advert|lead|date=August 2021}}
{{Advert|lead|date=August 2021}}
{{Use dmy dates|date=August 2018}}
{{Use dmy dates|date=August 2018}}
{{Use Indian English|date=August 2018}}
{{Use Indian English|date=August 2018}}
{{Infobox company
{{Infobox company
| name             = Indegene
| name = Indegene Limited
| logo             = File:Indegene Logo png.png
| logo = Indegene Logo png.png
| caption         =
| caption =  
| former_name     =
| former_name = Indegene Lifesystems Private Limited (1998–2016)<br/> Indegene Private Limited (2016–2022)
| type             = [[Privately held company|Private]]
| type = [[Public company|Public]]
| traded_as       =
| traded_as = {{ubl|{{NSE|INDGN}}|{{BSE|544172}}}}
| industry         = [[Health care]]
| industry = [[Pharmaceutical]] [[consultancy]]<ref>{{cite web | url=https://www.thehindubusinessline.com/markets/indegene-ends-26-higher-on-listing-day/article68171369.ece | title=Indegene ends 26% higher on listing day | date=13 May 2024 }}</ref>
| fate             =
| fate =  
| successor       =
| successor =  
| foundation       = {{Start date|1998}}
| foundation = {{Start date and age|1998}}
| founders         = Dr. Rajesh Nair (President)<br />Manish Gupta (CEO)<br />Dr. Sanjay Parikh (EVP)<br />Anand Kiran (EVP)<br />Gaurav Kapoor (EVP)
| founders = Rajesh Nair<br />Manish Gupta<br />Sanjay Parikh<br />Anand Kiran<br />Gaurav Kapoor
| hq_location     =  
| hq_location =  
| location_city   = [[Bangalore]]
| location_city = [[Bangalore]]
| location_country = India
| location_country = India
| area_served     = Worldwide
| area_served = Worldwide
| key_people       =
| key_people = Manish Gupta (CEO)<ref>{{cite news |title=Indegene on the prowl for global acquisitions |url=https://www.thehindubusinessline.com/companies/indegene-on-the-prowl-for-global-acquisitions/article32337770.ece |access-date=8 January 2023 |work=The Hindu Businessline |date=12 August 2020 |language=en}}</ref>
| products         =
| products =  
| production       =
| production =  
| revenue         =
| revenue = {{up}} {{INRConvert|2589|c}} (FY24)<ref name="fy24"/>
| operating_income =
| operating_income = {{up}} {{INRConvert|584|c}} (FY24)<ref name="fy24"/>
| net_income       =
| net_income = {{up}} {{INRConvert|336|c}} (FY24)<ref name="fy24">{{cite web |title=Fact Sheet – Q4 FY2024 |url=https://resources.indegene.com/indegene/investor-relations/quarterly-results/q4-2023-2024/fact-sheet-q4-fy2024.pdf |publisher=Indegene |access-date=30 May 2024}}</ref>
| assets           =
| assets =  
| equity           =
| equity =  
| parent           =
| parent =  
| owner            =
| owners = {{ubl|[[N. S. Raghavan]] (24.4%)|[[The Carlyle Group|Carlyle Group]] (10.22%)<ref>{{cite news |title=Carlyle Group sells 4.3% in Indegene for ₹636 cr |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/carlyle-group-sells-4-3-in-indegene-for-636-cr/articleshow/115945275.cms |access-date=4 December 2024 |work=The Economic Times |date=3 December 2024}}</ref>|Brighton Park Capital (9.55%)}}
| num_employees   =
| num_employees = 5,081 (March 2024)<ref name="fy24"/>
| homepage         = {{URL|http://www.indegene.com/}}
| homepage = {{URL|www.indegene.com}}
| footnotes       =
| footnotes =  
}}
}}


'''Indegene Inc.'''<ref name="Mint">{{cite news | last=Singh| first=Seema| title =Cutting pharma costs by intelligent marketing| newspaper =[[Mint (newspaper)|Mint]]| date =7 May 2009 | url =http://www.livemint.com/Companies/Wmpl5jnp7SG06Yrn6X5CIL/Cutting-pharma-costs-by-intelligent-marketing.html| access-date =2 October 2015}}</ref><ref name="BS2006">{{cite news | last=Unnikrishnan| first=CH| title =Indegene buys US firm| newspaper =[[Business Standard]]| date =8 November 2006 | url =http://www.business-standard.com/article/companies/indegene-buys-us-firm-106110801104_1.html| access-date =2 October 2015}}</ref> is a company offering [[research and development]] and management services to [[healthcare]] and [[pharmaceutical]] enterprises.<ref name="ETKart">{{cite news | last=Das| first=Avik| title =Flipkart, Practo CEOs get top rating from staff| newspaper =[[The Economic Times]]| date =2 September 2015 | url =http://articles.economictimes.indiatimes.com/2015-09-02/news/66143777_1_infosys-ceo-vishal-sikka-ceo-t-k-kurien-cent| access-date =2 October 2015}}</ref> It was founded in 1998 and is based in [[Bangalore]], [[India]].<ref name="Nikkei"/>
'''Indegene Limited''' is an Indian company that provides research and [[commercialization]] services to [[biopharmaceutical]] and [[healthcare]] enterprises.<ref name="ETKart">{{cite news | last=Das| first=Avik| title =Flipkart, Practo CEOs get top rating from staff| newspaper =[[The Economic Times]]| date =2 September 2015 | url =http://articles.economictimes.indiatimes.com/2015-09-02/news/66143777_1_infosys-ceo-vishal-sikka-ceo-t-k-kurien-cent| archive-url =https://web.archive.org/web/20150908022908/http://articles.economictimes.indiatimes.com/2015-09-02/news/66143777_1_infosys-ceo-vishal-sikka-ceo-t-k-kurien-cent| url-status =dead| archive-date =8 September 2015| access-date =2 October 2015}}</ref><ref name="Mint">{{cite news | last=Singh| first=Seema| title =Cutting pharma costs by intelligent marketing| newspaper =[[Mint (newspaper)|Mint]]| date =7 May 2009 | url =http://www.livemint.com/Companies/Wmpl5jnp7SG06Yrn6X5CIL/Cutting-pharma-costs-by-intelligent-marketing.html| access-date =2 October 2015}}</ref><ref name="BS2006">{{cite news | last=Unnikrishnan| first=CH| title =Indegene buys US firm| newspaper =[[Business Standard]]| date =8 November 2006 | url =http://www.business-standard.com/article/companies/indegene-buys-us-firm-106110801104_1.html| access-date =2 October 2015}}</ref> Based in [[Bangalore]], the company provides consulting in [[pharmaceutical marketing]], [[clinical trial]]s, [[pharmacovigilance]], [[Medical science liaison|medical]] and [[regulatory affairs]], and [[health informatics]].<ref name="Nikkei">{{cite news | last=Murayama| first=Keiichi| title =India's tech muscle has the world's attention | newspaper =[[The Nikkei]]| date =19 February 2015 | url =http://asia.nikkei.com/magazine/20150219-India-s-got-the-bright-stuff/On-the-Cover/India-s-tech-muscle-has-the-world-s-attention?page=2| access-date =2 October 2015}}</ref><ref name="Revenue">{{cite news |title=Indegene files papers with Sebi; eyes ₹3,200 crore via IPO |url=https://www.livemint.com/market/ipo/indegene-files-papers-with-sebi-eyes-rs-3-200-crore-via-ipo-11671103045857.html |access-date=8 January 2023 |work=mint |date=15 December 2022 |language=en}}</ref>


Indegene has offices in North America, Europe, China and India.
==History==
<ref name="NFV">{{cite news | title =Indegene acquires MedCases, LLC| publisher =NFV Zone| date =30 November 2006 | url =http://www.nfvzone.com/news/2006/11/30/2123279.htm| access-date =2 October 2015}}</ref>
Indegene was founded in 1998 by Dr. Rajesh Nair, Manish Gupta, Gaurav Kapoor, Dr.Sanjay Parikh and Anand Kiran.<ref name="ETCallCentre">{{cite news | last=Amirapu| first=Deepika| title =Indegene eyes US call centre buy for $10–15 million| newspaper =[[The Economic Times]]| date =9 March 2012 | url =http://articles.economictimes.indiatimes.com/2012-03-09/news/31139486_1_indegene-lifesystems-marketing-medical-education| archive-url =https://web.archive.org/web/20151119075559/http://articles.economictimes.indiatimes.com/2012-03-09/news/31139486_1_indegene-lifesystems-marketing-medical-education| url-status =dead| archive-date =19 November 2015| access-date =2 October 2015}}</ref> Indegene's first acquisition was Medsn, a company that provided medical education. Medsn continued to operate under the same name in the United States.<ref name="ETMed">{{cite news | last=D'Silva| first=Jeetha| title =Indegene acquires US medical education co| newspaper =[[The Economic Times]]| date =17 September 2005 | url =http://articles.economictimes.indiatimes.com/2005-09-17/news/27506888_1_equity-firm-ge-equity-subsidiary| archive-url =https://web.archive.org/web/20151016233025/http://articles.economictimes.indiatimes.com/2005-09-17/news/27506888_1_equity-firm-ge-equity-subsidiary| url-status =dead| archive-date =16 October 2015| access-date =2 October 2015}}</ref> In 2008, Medsn officially became Indegene Pharmaceutical Solutions in the United States. In 2006, Indegene acquired MedCases, a [[continuing medical education]] company based in the United States.<ref name="BS2006"/><ref name="NFV"/>
 
In 2009, Indegene signed a [[master service agreement]] with six pharmaceutical companies.<ref name="Mint"/><ref name="PBOptimax">{{cite news| title =Indegene highlights benefits of patient adherence programs for pharma cos| publisher =PharmaBiz| date =3 June 2011| url =http://pharmabiz.com/NewsDetails.aspx?aid=63241&sid=2| access-date =2 October 2015| archive-date =19 November 2015| archive-url =https://web.archive.org/web/20151119144237/http://pharmabiz.com/NewsDetails.aspx?aid=63241&sid=2| url-status =dead}}</ref> The following year, Indegene acquired [[Canada]]-based Aptilon, a [[multichannel marketing]] firm, for $4 million.<ref name="TOICanada">{{cite news | last=Mukherjee| first=Rupali| title =Indegene to acquire Canada-based company for $4 million | newspaper =[[Times of India]]| date =7 November 2012 | url =http://timesofindia.indiatimes.com/business/india-business/Indegene-to-acquire-Canada-based-company-for-4-million/articleshow/17133296.cms| access-date =2 October 2015}}</ref> The company subsequently acquired [[Atlanta]]-based Total Therapeutic Management in 2014.<ref name="TTM">{{cite news | last=Craig| first=Tara| title =Indegene acquires Total Therapeutic Management | publisher =PMLive.com| date =9 January 2014 | url =http://www.pmlive.com/pharma_news/indegene_acquires_total_therapeutic_management_532004| access-date =2 October 2015}}</ref>
 
In September 2019, Indegene acquired London-based consulting company, DT Associates, for $10 million.<ref>{{cite news |last1=Balakrishnan |first1=Reghu |title=Healthcare tech firm Indegene acquires DT Associates |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/healthcare-tech-firm-indegene-acquires-dt-associates/articleshow/70960667.cms |access-date=28 April 2024 |work=The Economic Times |date=3 September 2019}}</ref>
 
In February 2021, [[the Carlyle Group]] and Brighton Park Capital invested $200 million in Indegene.<ref name="LiveMint">{{cite news | last=Madhurima| first=Nandy| title =Indegene to raise $200 mn from Carlyle, Brighton Park| newspaper =[[LiveMint]]| date =3 February 2021 | url =https://www.livemint.com/companies/start-ups/indegene-to-raise-200-mn-from-carlyle-brighton-park-11612286897793.html| access-date =20 August 2021}}</ref> In August 2021, Indegene acquired Medical Marketing Economics (MME), an American [[market access]] and [[pricing science|pricing strategy]] company, for $10 million.<ref>{{cite news |last1=Baruah |first1=Ayushman |title=Indegene acquires US-based Medical Marketing Economics for $10 mn |url=https://www.livemint.com/companies/news/indegene-acquires-us-based-medical-marketing-economics-for-10-mn-11630322193354.html |access-date=28 April 2024 |work=Mint |date=30 August 2021 |language=en}}</ref>


==History==
Indegene went [[Public company|public]] in May 2024 with an [[initial public offering]], raising {{INRconvert|1842|c}}. It listed on the [[Bombay Stock Exchange|BSE]] and the [[National Stock Exchange of India|NSE]].<ref>{{cite news |last1=Narayanan |first1=KS Badri |title=Indegene IPO opens today in ₹430-452 price band |url=https://www.thehindubusinessline.com/markets/ipo-screener-indegene-issue-opens-today-in-430-452-price-band/article68143174.ece |access-date=6 May 2024 |work=BusinessLine |date=6 May 2024 |language=en}}</ref><ref name="fy23">{{cite news |title=PE firms Carlyle, Nadathur Fareast, Brighton Park Capital-backed Indegene IPO to open on May 6 |url=https://www.moneycontrol.com/news/business/ipo/pe-firms-carlyle-nadathur-fareast-brighton-park-capital-backed-indegene-ipo-to-open-on-may-6-12709591.html |access-date=28 April 2024 |work=Moneycontrol}}</ref>
Indegene was founded in 1998 by Dr. Rajesh Nair, Manish Gupta, Gaurav Kapoor, Dr.Sanjay Parikh and Anand Kiran.<ref name="ETCallCentre">{{cite news | last=Amirapu| first=Deepika| title =Indegene eyes US call centre buy for $10–15 million| newspaper =[[The Economic Times]]| date =9 March 2012 | url =http://articles.economictimes.indiatimes.com/2012-03-09/news/31139486_1_indegene-lifesystems-marketing-medical-education| access-date =2 October 2015}}</ref> Indegene's first acquisition was Medsn, a company that provided medical education. Medsn continued to operate under that name in the United States.<ref name="ETMed">{{cite news | last=D'Silva| first=Jeetha| title =Indegene acquires US medical education co| newspaper =[[The Economic Times]]| date =17 September 2005 | url =http://articles.economictimes.indiatimes.com/2005-09-17/news/27506888_1_equity-firm-ge-equity-subsidiary| access-date =2 October 2015}}</ref> In 2008, Medsn officially became known as Indegene Pharmaceutical Solutions in the United States.<ref name="PRMedsn">{{cite news | title =Medsn to Become Indegene Pharmaceutical Solutions, Inc.: Change Signifies the Success of Its Innovative Global Services Model | publisher =[[PR Newswire]]| date =14 May 2008 | url =http://www.prnewswire.com/news-releases/medsn-to-become-indegene-pharmaceutical-solutions-inc-change-signifies-the-success-of-its-innovative-global-services-model-57250467.html| access-date =2 October 2015}}</ref> In 2006, Indegene acquired MedCases, a [[continuing medical education]] company based in the United States.<ref name="BS2006"/><ref name="NFV"/>


In 2009, Indegene signed a [[master service agreement]] with six pharmaceutical companies.<ref name="Mint"/><ref name="PBOptimax">{{cite news | title =Indegene highlights benefits of patient adherence programs for pharma cos | publisher =PharmaBiz| date =3 June 2011 | url =http://pharmabiz.com/NewsDetails.aspx?aid=63241&sid=2| access-date =2 October 2015}}</ref> The following year, Indegene acquired [[Canada]]-based Aptilon, a [[multichannel marketing]] firm, for $4 million.<ref name="TOICanada">{{cite news | last=Mukherjee| first=Rupali| title =Indegene to acquire Canada-based company for $4 million | newspaper =[[Times of India]]| date =7 November 2012 | url =http://timesofindia.indiatimes.com/business/india-business/Indegene-to-acquire-Canada-based-company-for-4-million/articleshow/17133296.cms| access-date =2 October 2015}}</ref> The company subsequently acquired [[Atlanta]]-based Total Therapeutic Management in 2014.<ref name="TTM">{{cite news | last=Craig| first=Tara| title =Indegene acquires Total Therapeutic Management | publisher =PMLive.com| date =9 January 2014 | url =http://www.pmlive.com/pharma_news/indegene_acquires_total_therapeutic_management_532004| access-date =2 October 2015}}</ref> In February 2021, Carlyle and Brighton Park agreed to invest US $200 million in Indegene <ref name="LiveMint">{{cite news | last=Madhurima| first=Nandy| title =Indegene to raise $200 mn from Carlyle, Brighton Park| newspaper =[[LiveMint]]| date =3 February 2021 | url =https://www.livemint.com/companies/start-ups/indegene-to-raise-200-mn-from-carlyle-brighton-park-11612286897793.html| access-date =20 August 2021}}</ref>
==Operations==
Indegene has offices in India, the United States, the [[European Union]], and [[Asia-Pacific]].<ref name="PB2012">{{cite news| last =Vijay| first =Nandita| title =Indegene plans next phase of growth through acquisition in US, EU markets| publisher =PharmaBiz| date =7 November 2012| url =http://pharmabiz.com/NewsDetails.aspx?aid=72031&sid=1| access-date =2 October 2015| archive-date =19 November 2015| archive-url =https://web.archive.org/web/20151119144607/http://pharmabiz.com/NewsDetails.aspx?aid=72031&sid=1| url-status =dead}}</ref><ref name="NFV">{{cite news | title =Indegene acquires MedCases, LLC| publisher =NFV Zone| date =30 November 2006 | url =http://www.nfvzone.com/news/2006/11/30/2123279.htm| access-date =2 October 2015}}</ref>


In 2011 and 2012, ''[[The Economic Times]]'' named Indegene one of the best companies to work for in the Professional Services industry.<ref name="ETBest">{{cite news | title =Best companies to work for 2012: Companies that came up trumps across various sectors| newspaper =[[The Economic Times]]| date =16 July 2012 | url =http://articles.economictimes.indiatimes.com/2012-07-16/news/32698621_1_india-s-best-companies-vodafone-india-work-institute| access-date =2 October 2015}}</ref> In 2012, Indegene had 900 employees in offices in India, the United States, the [[European Union]], and [[China]]. <ref name="PB2012">{{cite news | last=Vijay| first=Nandita| title =Indegene plans next phase of growth through acquisition in US, EU markets | publisher =PharmaBiz| date =7 November 2012 | url =http://pharmabiz.com/NewsDetails.aspx?aid=72031&sid=1| access-date =2 October 2015}}</ref> By 2021, the number of employees at Indegene increased to 4,100.<ref name="Nikkei">{{cite news | last=Murayama| first=Keiichi| title =India's tech muscle has the world's attention | newspaper =[[The Nikkei]]| date =19 February 2015 | url =http://asia.nikkei.com/magazine/20150219-India-s-got-the-bright-stuff/On-the-Cover/India-s-tech-muscle-has-the-world-s-attention?page=2| access-date =2 October 2015}}</ref>
In 2011 and 2012, ''[[The Economic Times]]'' named Indegene one of the best companies to work for in the Professional Services industry.<ref name="ETBest">{{cite news | title =Best companies to work for 2012: Companies that came up trumps across various sectors| newspaper =[[The Economic Times]]| date =16 July 2012 | url =http://articles.economictimes.indiatimes.com/2012-07-16/news/32698621_1_india-s-best-companies-vodafone-india-work-institute| archive-url =https://archive.today/20130411034848/http://articles.economictimes.indiatimes.com/2012-07-16/news/32698621_1_india-s-best-companies-vodafone-india-work-institute| url-status =dead| archive-date =11 April 2013| access-date =2 October 2015}}</ref>


==References==
==References==
{{reflist}}
{{reflist}}


[[Category:Companies based in Bangalore]]
{{Contract research organization}}
 
[[Category:Companies based in Bengaluru]]
[[Category:Indian companies established in 1998]]
[[Category:Indian companies established in 1998]]
[[Category:1998 establishments in Karnataka]]
[[Category:1998 establishments in Karnataka]]
[[Category:Health care companies established in 1998]]
[[Category:Health care companies established in 1998]]
[[Category:Companies listed on the National Stock Exchange of India]]
[[Category:Companies listed on the Bombay Stock Exchange]]
[[Category:2024 initial public offerings]]
[[Category:The Carlyle Group companies]]

Latest revision as of 01:51, 18 August 2025


Indegene Limited
Formerly
Indegene Lifesystems Private Limited (1998–2016)
Indegene Private Limited (2016–2022)
Traded as
IndustryPharmaceutical consultancy[1]
Founded1998; 28 years ago (1998)
Founder(s)sRajesh Nair
Manish Gupta
Sanjay Parikh
Anand Kiran
Gaurav Kapoor
Headquarters
Bangalore
,
India
Area served
Worldwide
Key people
Manish Gupta (CEO)[2]
RevenueIncrease ₹2,589 crore (US$360 million) (FY24)[3]
Increase ₹584 crore (US$82 million) (FY24)[3]
Increase ₹336 crore (US$47 million) (FY24)[3]
Owners
Number of employees
5,081 (March 2024)[3]
Websitewww.indegene.com

Indegene Limited is an Indian company that provides research and commercialization services to biopharmaceutical and healthcare enterprises.[5][6][7] Based in Bangalore, the company provides consulting in pharmaceutical marketing, clinical trials, pharmacovigilance, medical and regulatory affairs, and health informatics.[8][9]

History[edit | edit source]

Indegene was founded in 1998 by Dr. Rajesh Nair, Manish Gupta, Gaurav Kapoor, Dr.Sanjay Parikh and Anand Kiran.[10] Indegene's first acquisition was Medsn, a company that provided medical education. Medsn continued to operate under the same name in the United States.[11] In 2008, Medsn officially became Indegene Pharmaceutical Solutions in the United States. In 2006, Indegene acquired MedCases, a continuing medical education company based in the United States.[7][12]

In 2009, Indegene signed a master service agreement with six pharmaceutical companies.[6][13] The following year, Indegene acquired Canada-based Aptilon, a multichannel marketing firm, for $4 million.[14] The company subsequently acquired Atlanta-based Total Therapeutic Management in 2014.[15]

In September 2019, Indegene acquired London-based consulting company, DT Associates, for $10 million.[16]

In February 2021, the Carlyle Group and Brighton Park Capital invested $200 million in Indegene.[17] In August 2021, Indegene acquired Medical Marketing Economics (MME), an American market access and pricing strategy company, for $10 million.[18]

Indegene went public in May 2024 with an initial public offering, raising ₹1,842 crore (US$260 million). It listed on the BSE and the NSE.[19][20]

Operations[edit | edit source]

Indegene has offices in India, the United States, the European Union, and Asia-Pacific.[21][12]

In 2011 and 2012, The Economic Times named Indegene one of the best companies to work for in the Professional Services industry.[22]

References[edit | edit source]

  1. ↑ "Indegene ends 26% higher on listing day". 13 May 2024.
  2. ↑ "Indegene on the prowl for global acquisitions". The Hindu Businessline. 12 August 2020. Retrieved 8 January 2023.
  3. ↑ 3.0 3.1 3.2 3.3 "Fact Sheet – Q4 FY2024" (PDF). Indegene. Retrieved 30 May 2024.
  4. ↑ "Carlyle Group sells 4.3% in Indegene for ₹636 cr". The Economic Times. 3 December 2024. Retrieved 4 December 2024.
  5. ↑ Das, Avik (2 September 2015). "Flipkart, Practo CEOs get top rating from staff". The Economic Times. Archived from the original on 8 September 2015. Retrieved 2 October 2015.
  6. ↑ 6.0 6.1 Singh, Seema (7 May 2009). "Cutting pharma costs by intelligent marketing". Mint. Retrieved 2 October 2015.
  7. ↑ 7.0 7.1 Unnikrishnan, CH (8 November 2006). "Indegene buys US firm". Business Standard. Retrieved 2 October 2015.
  8. ↑ Murayama, Keiichi (19 February 2015). "India's tech muscle has the world's attention". The Nikkei. Retrieved 2 October 2015.
  9. ↑ "Indegene files papers with Sebi; eyes ₹3,200 crore via IPO". mint. 15 December 2022. Retrieved 8 January 2023.
  10. ↑ Amirapu, Deepika (9 March 2012). "Indegene eyes US call centre buy for $10–15 million". The Economic Times. Archived from the original on 19 November 2015. Retrieved 2 October 2015.
  11. ↑ D'Silva, Jeetha (17 September 2005). "Indegene acquires US medical education co". The Economic Times. Archived from the original on 16 October 2015. Retrieved 2 October 2015.
  12. ↑ 12.0 12.1 "Indegene acquires MedCases, LLC". NFV Zone. 30 November 2006. Retrieved 2 October 2015.
  13. ↑ "Indegene highlights benefits of patient adherence programs for pharma cos". PharmaBiz. 3 June 2011. Archived from the original on 19 November 2015. Retrieved 2 October 2015.
  14. ↑ Mukherjee, Rupali (7 November 2012). "Indegene to acquire Canada-based company for $4 million". Times of India. Retrieved 2 October 2015.
  15. ↑ Craig, Tara (9 January 2014). "Indegene acquires Total Therapeutic Management". PMLive.com. Retrieved 2 October 2015.
  16. ↑ Balakrishnan, Reghu (3 September 2019). "Healthcare tech firm Indegene acquires DT Associates". The Economic Times. Retrieved 28 April 2024.
  17. ↑ Madhurima, Nandy (3 February 2021). "Indegene to raise $200 mn from Carlyle, Brighton Park". LiveMint. Retrieved 20 August 2021.
  18. ↑ Baruah, Ayushman (30 August 2021). "Indegene acquires US-based Medical Marketing Economics for $10 mn". Mint. Retrieved 28 April 2024.
  19. ↑ Narayanan, KS Badri (6 May 2024). "Indegene IPO opens today in ₹430-452 price band". BusinessLine. Retrieved 6 May 2024.
  20. ↑ "PE firms Carlyle, Nadathur Fareast, Brighton Park Capital-backed Indegene IPO to open on May 6". Moneycontrol. Retrieved 28 April 2024.
  21. ↑ Vijay, Nandita (7 November 2012). "Indegene plans next phase of growth through acquisition in US, EU markets". PharmaBiz. Archived from the original on 19 November 2015. Retrieved 2 October 2015.
  22. ↑ "Best companies to work for 2012: Companies that came up trumps across various sectors". The Economic Times. 16 July 2012. Retrieved 2 October 2015.{{cite news}}: CS1 maint: deprecated archival service (link)

Template:Contract research organization

Retrieved from "https://en.bharatpedia.org/w/index.php?title=Indegene&oldid=452221"
Discover more